SEVILLE, Spain — Whether atropine should be the standard of care for halting myopia progression was a hot topic discussed at the Congress on Controversies in Ophthalmology.
Myopia has become a global epidemic and is associated with complications such as myopic macular degeneration, retinal detachment, cataract and open-angle glaucoma.
“We know that slowing myopia progression by only 1 D can significantly reduce the risk of vision-threatening conditions,” Andrzej Grzybowski, MD, PhD, said.
In his opinion, atropine in myopia control is cost-effective and safe, Grzybowski said. In